Posted By: Chris Sandburg
Chris Sandburg

This user hasn't shared any profile information

OXIS International, Inc. (OTCMKTS:OXIS) just announced that it has entered into a sponsored research agreement with the University of Minnesota, designed to help forward the development of one of its preclinical assets. This is a company we’ve...

Earlier on this week, we highlighted a small cap biotech called Kadmon Holdings Inc (NYSE:KDMN) as a company to watch this year. What flagged our attention was the heavy institutional interest that looked to be accruing in the stock, with big...

Towards the end of last year, we took a look at a small biotech play called Q BioMed Inc (OTCMKTS:QBIO). The company had just logged some gains, and had drawn our attention on the back of this run. At that point, Q BioMed was going for around...

Industry opinion on patent protection and enforcement varies considerably depending on who you talk to. Some argue patent protection incentivizes fresh development and creativity, as without it inventors would see no point in developing new...

Cellceutix Corp (OTCMKTS:CTIX) has been subject to some pretty harsh criticism as late, and is currently at the center of a legal dispute between it and an anonymous SA blogger called Mako Research surrounding a report it put out that seemingly...

Medical Marijuana Inc (OTCMKTS:MJNA) is down around 10% this week, and the company is down around 35% year to date. It’s struggled to maintain the positive sentiment that it picked up in the wake of the cannabis legalization rush during...

We like to keep our coverage varied here at Insider Financial, but now and again, markets dictate that we revisit a company almost as soon as we’ve taken a look at it. One such situation just presented itself with development stage biotechnology...

Viaderma Inc (OTCMKTS:VDRM) is an early runner in the micro cap space this week. The company is up close to 35% on its weekly open, and looks set to register further gains as action matures throughout the session on Tuesday. What is driving...

For the last eighteen months, Anavex Life Sciences Corp. (NASDAQ:AVXL) has been at the the center of a great debate. From the company falling foul of an army of short sellers, to management overpaying themselves, to the science being made up,...

Bellerophon Therapeutics Inc (NASDAQ:BLPH) is all over the place at the moment. The company traded for around $.50 a share back in January, and ran up to highs of just shy of $2 a share at the beginning of this month. At the end of last week,...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter